ATLANTA, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to ...

ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to ...

The number of women who sought permanent birth control via surgery increased in the wake of Roe v. Wade's overturn in 2022 Researchers saw a 51% increase in tubal ligation in four states “There was a ...

ATLANTA, June 26, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (FEMY), a biomedical company aiming to meet women’s needs worldwide by developing a suite of product candidates that include minimally invasive, ...

ATLANTA, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to ...

One woman shares her story of undergoing tubal ligation, one of the permanent methods of birth control, only to discover months later that she was pregnant again with her fourth child. It was the last ...

ATLANTA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting women’s unmet needs worldwide by developing a broad portfolio of innovative product ...